Roman Denk

Corporate Secretary, Management of corporate Intellectual Property, Secretary to the Board of Directors, Corporate reporting for Board of Directors and selected shareholders, Restructuring of manufacturing facility in Turku ( Finland), Development of a German Investment Fund for pharmaceutical reformulation products

Sale of remaining minority shares to CeloNova BioSciences Inc.; Newnan, USA; Adoption of company to US requirements and practices; set-up of R&D facility in Heidelberg; enlargement of production; 12 employees in R&D and production (more in Europe and in the US); Development of second product (Embozene Microparticles for Embolization therapy); Product accepted according to European guideline 92/43 EWG); Clinical trials and market introduction initiated

Founder and Managing Shareholder Start-Up for exploiting own patented idea in the field of medical devices; Development of a business plan, set up of company, first round financing with industrial and private equity investors, business and product development, governmental admissions, start of production, certification according to DIN EN ISO 13485 and 9001, start of sales of first product (cardiovascular stent)

Establishing three new departments: Pharmaceuticals, Medical Devices and Chemistry Consulting inventors and universities, evaluation of inventions, development of patent- and marketing strategies, IP- Management, negotiation and supervision of contracts (cooperation agreements, patents and licenses)

Patent applications, opposition proceedings, research

Metal and hair analysis, toxicological expertises

Analytik, Organische Chemie, Physikalische Chemie